Key Highlights

● GE HealthCare Technologies closed at $69.57 on October 16, trading below the analyst target.

● The consensus 12-month price target is $82.70, implying about 18.9% upside.

● Analysts are split 16 Buy, 5 Hold, and 0 Sell on the stock.

● Targets range from $70 to $96 across 21 analysts.

GE HealthCare Technologies Inc. (NASDAQ:GEHC) closed at $69.57 on October 16, 2026, according to market data. The stock is a constituent of the Nasdaq-100 and trades on the Nasdaq. The consensus analyst price target is $82.70, which is 18.9% above the latest close, implying 18.9% upside. The shares are drawing attention this week because of fresh analyst activity and upcoming earnings: the next results are expected on October 28, 2026 (Q3 2026, before market open).

What Is the Latest Analyst Price Target?

The mean consensus target is $82.70 across 21 analysts, with a median of $84.00. Individual forecasts range from a low of $70.00 to a high of $96.00. Measured against the 16 October close of $69.57, the consensus target suggests 18.9% upside. The analyst data on the source page was last updated on October 12, 2026, so the consensus may not reflect actions since then. These figures are forecasts, not guarantees, and different data providers can show slightly different consensus numbers because of timing and methodology.

What Are Analysts Saying?

The overall consensus rating is Buy, with the ratings split as 16 Buy (10 Strong Buy, 6 Buy), 5 Hold, 0 Sell. Recent broker actions include the following. BTIG (12 Oct) kept a Buy rating but trimmed its target to $75 from $79; Barclays (7 Oct) initiated at Buy with an $85 target; Needham (5 Oct) reiterated Buy at $93; Citi (5 Oct) kept a Hold rating and lowered its target to $71 from $75; and RBC Capital (1 Oct) maintained Buy at $80.

The lowest target ($70) sits only marginally above the current price, while several recent target revisions (BTIG, Citi) have been downward.

What Could Help the Stock Reach the Price Target?

If the consensus proves accurate, the shares would need to close the gap to $82.70. Several factors could support that outcome. Company developments are one: On October 5, 2026 the company announced an agreement to acquire SOFIE Biosciences for $945 million in cash, and on 22 September it raised its quarterly dividend by 14% to $0.04 per share. It has also announced a Q3 2026 results date of 28 October.

Beyond this, results that meet or exceed expectations, firm guidance and stable sector conditions would typically support analyst estimates and could encourage further target upgrades. Equally, a broadly supportive market backdrop can narrow the gap between price and targets. None of these outcomes is assured.

What Could Prevent the Stock Reaching the Target?

Analyst targets are opinions about a twelve-month horizon and are frequently revised. Earnings that fall short of expectations, weaker guidance, changes in interest rates, regulatory or policy shifts and wider market volatility could all cause the shares to underperform the consensus. The spread between the lowest target ($70.00) and highest target ($96.00) shows that professional forecasters do not agree on fair value. Investors should also note that consensus figures can lag recent events, so the numbers cited here may already have been overtaken by newer broker notes.

What Should Investors Watch Next?

The key event is the next earnings report, expected on October 28, 2026 (Q3 2026, before market open). Investors may wish to watch management commentary and guidance, any changes to broker ratings and targets following the results, and the direction of the consensus mean and median in the weeks ahead. Any further company announcements, such as acquisitions, dividends or leadership changes, may also influence sentiment.

Still Room to Climb

On the verified figures, GE HealthCare Technologies Inc. (GEHC) closed at $69.57 on October 16, 2026, while the analyst consensus target of $82.70 suggests 18.9% upside, with a Buy consensus rating across 21 analysts.